Komen Foundation Announces 1998 Postdoctoral Fellows

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

DALLAS--The Susan G. Komen Breast Cancer Foundation has announced the recipients of its 1998 postdoctoral fellowship grants, which total more than $1 million. In addition to these 10 new first-year grant recipients, the Komen Foundation currently funds 21 previously awarded fellowships throughout the United States.

DALLAS--The Susan G. Komen Breast Cancer Foundation has announced the recipients of its 1998 postdoctoral fellowship grants, which total more than $1 million. In addition to these 10 new first-year grant recipients, the Komen Foundation currently funds 21 previously awarded fellowships throughout the United States.

These fellowships represent the Foundation’s continued commitment to recruiting and retaining young scientists in the field of breast cancer research and to funding innovative, cutting-edge research. For example, a 1997 grant went to Wei Wen, PhD, and her sponsor Judah Folkman, MD, for further study of the angiogenesis inhibitor endostatin.

Each year, the Foundation’s National Research Fellowship Program offers postdoctoral fellowship grants for breast cancer research to qualified applicants with MD or PhD degrees.

The 3-year grant offers an experienced breast cancer investigator the opportunity to select a postdoctoral fellow to train in his or her laboratory. Grant recipients are selected through a peer-review process that is recognized by the National Cancer Institute. The annual stipend is $35,000 per award.

For more information about the grants program, contact Elda Railey, director of grants, via email at grants@komen.org or by calling 888-300-5582.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content